Virtual reality treatment for people with lived experience of visual hallucination Mental and Behavioural Disorders
Conditions
Interventions
To achieve these aims, there are three work-streams which map onto our three main objectives. At the heart of this study is the focus on developing a novel and powerful intervention. The MRC guideline
Sponsors
Cumbria Northumberland Tyne and Wear NHS Foundation Trust
Eligibility
Sex/Gender
All
Age
16 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 16 and above (upper age limit will be determined by the teams recruited from which is usually about 65) 2. Receiving care from Early Intervention in Psychosis services or community treatment teams 3. Meets ICD11 criteria for schizophrenia, schizoaffective disorder or diagnosis of schizophrenia spectrum psychosis (F20-29) or entry criteria for an Early Intervention in Psychosis service 4. Have a history of Visual Hallucinations (VH) for at least three months 5. Would like to receive a psychological intervention specifically for VH 6. Have the capacity to provide written informed consent 7. Be judged by their clinician to be clinically stable for the preceding 4 weeks
Exclusion criteria
Exclusion criteria: 1. Any intellectual disability or severe cognitive dysfunction precluding their ability to provide informed consent. 2. Any primary diagnosis of substance misuse dependency or traumatic brain injuries, organic psychoses, or dementia. 3. Unable to use VR (owing to epilepsy, poor eyesight or dizziness).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The feasibility and acceptability of VUSE and VR intervention measured using data collected during feedback from patient participants, closely monitoring any changes in the reported frequency, distress and impact on the interviewer-led (PSYRATS VH) and self-report measure of visual hallucinations (Hamilton) | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome measures will inform the next step in the research about what the most effective measures are to use in the definitive trial, assessed at pre- and post-treatment (6 and 12 weeks) and follow-up (16 weeks): 1. Distress and disability caused by hallucinations assessed using the (hallucinations) Multi-Modality Unusual Sensory Experiences Questionnaire (MUSEQ) and (MMHM), (paranoia) revised Green et al., Paranoid Thoughts Scale (R-GPTS), and (general distress) General Anxiety Disorder-7 and Patient Health Questionnaire-9 (GAD 7, PHQ-9) 2. Quality of life, stigma and functioning measures collected by the self-report questionnaires: Questionnaire about the Process of Recovery, Internalized Stigma of Mental Illness Scale-9 and Dialogue in Life and Treatment Outcome Goals (QPR, ISMI-9, and DIALOG) 3. Satisfaction with therapy and working alliance will be captured by self-reported measures: Satisfaction with Therapy and Therapist Scale-Revised and Working Alliance Inventory (STTS-R and WAI) at the end of treatment | — |
Countries
England, United Kingdom
Contacts
Public ContactRob Dudley
Outcome results
None listed